This study established the rationale for evaluating the enhanced efficacy of GV1001 in combination with GM-CSF and gemcitabine in non-resectable PDA patients with a life expectancy of at least 3 months [155]. This evidence concerns the gene CSF2 and Patent ductus arteriosus.